JPMorgan Chase & Co’s Actinium Pharmaceuticals ATNM Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $26.1K | Sell |
18,617
-2,507
| -12% | -$3.51K | ﹤0.01% | 5271 |
|
|
2025
Q1 | $34K | Sell |
21,124
-102,707
| -83% | -$165K | ﹤0.01% | 5141 |
|
|
2024
Q4 | $156K | Buy |
123,831
+110,141
| +805% | +$139K | ﹤0.01% | 4625 |
|
|
2024
Q3 | $25.7K | Sell |
13,690
-205
| -1% | -$385 | ﹤0.01% | 5157 |
|
|
2024
Q2 | $103K | Buy |
13,895
+2,111
| +18% | +$15.6K | ﹤0.01% | 4586 |
|
|
2024
Q1 | $92.3K | Sell |
11,784
-6,788
| -37% | -$53.2K | ﹤0.01% | 4763 |
|
|
2023
Q4 | $94.3K | Buy |
18,572
+452
| +2% | +$2.3K | ﹤0.01% | 4791 |
|
|
2023
Q3 | $107K | Sell |
18,120
-2,048
| -10% | -$12.1K | ﹤0.01% | 4564 |
|
|
2023
Q2 | $150K | Buy |
+20,168
| New | +$150K | ﹤0.01% | 4439 |
|
|
2016
Q2 | – | Sell |
-3
| Closed | – | – | 4238 |
|
|
2016
Q1 | $0 | Buy |
+3
| New | – | ﹤0.01% | 4136 |
|